News
Bevacizumab added to Proposition 65 List
13th Mar 2019
Bevacizumab has been added to the list based on a formal requirement by the US Food and Drug Administration (FDA) that the chemical be identified or labeled as causing reproductive toxicity (developmental and female endpoints).
Businesses are required to provide a clear and reasonable warning before knowingly and intentionally exposing anyone to Prop65 listed chemicals one year after being added to the list.
Get in touch to find out how we can help with your compliance requirements
EMEA:
+44 (0) 1869 255758
/
US:
+1 (800) 450 2403
/
Email:
sales@thecompliancemap.com
ECHA publishes report on enforcement with authorisation requirement of REACH
8th Mar 2023
Read article